Talk to any cancer researcher or doctor today and what you hear is wonder and hope.

Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.

Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

New Global Head of Cardiovascular and Metabolic Diseases Research looks to apply new tools to address tough challenges.

A complex protein module keeps the liver’s biochemical factory running smoothly and at capacity.

Ask Alan Frohman how he found out that he had glaucoma, and he'll quickly tell you that there were no warning signs.

Team uncovers a potential therapeutic approach for patients deficient in a protein called Shank3.

Novartis researchers are searching for more effective ways to discover drugs for neurological and psychiatric diseases.